Want to see SVRA full AI Analyst Report?
SVRA Stock Chart & Stats
$5.78
$0.04(1.15%)
At close: 4:00 PM EST
$5.78
$0.04(1.15%)
Day’s Range― - ―
52-Week Range$2.38 - $7.01
Previous CloseN/A
Volume189.20K
Average Volume (3M)1.87M
Market Cap
$1.13B
Enterprise Value$1.21K
Total Cash (Recent Filing)$202.77M
Total Debt (Recent Filing)$30.11M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding204,927,220
10 Day Avg. Volume1,582,444
30 Day Avg. Volume1,865,575
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.17Price Target Upside93.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$3.18M
Bulls Say, Bears Say
Bulls Say
Orphan-disease Focus (inhaled Molgramostim)Savara's concentration on a single, rare respiratory indication gives the company a clear, durable commercial objective: if inhaled molgramostim obtains approval, the small, well‑defined patient population and limited direct competition support sustainable pricing, predictable demand and a focused commercialization path that can drive long‑term revenues versus broad, crowded markets.
Manageable LeverageReported debt levels are modest relative to equity, implying lower immediate interest burden and some balance sheet flexibility to support ongoing R&D and regulatory activities. This structural leverage profile reduces short‑term solvency pressure compared with highly indebted peers, extending the time window for clinical progress before forced capital restructuring.
Leadership Continuity Via Internal CFO/COO AppointmentPromoting the existing COO into the combined CFO/COO role preserves institutional knowledge and operational continuity during a critical clinical and financing phase. Internal succession reduces transition risk, helps align financial planning with operations and may improve execution consistency for long‑range development, regulatory and commercialization planning.
Bears Say
No Revenue; Widening LossesSavara remains a pre‑commercial biotech with no product sales and materially widening losses, which is a durable constraint on self‑funding. Continued negative earnings erode equity, increase reliance on external capital, and heighten execution risk because sustained clinical or regulatory delays would further compress financial flexibility and investor tolerance.
Accelerating Cash BurnOperating and free cash flows are substantially negative and have increased over time, meaning cash consumption is a real, ongoing drain rather than an accounting artifact. This persistent burn profile creates durable funding needs, raising the probability of future equity financings, partnership pressure or program cutbacks if clinical timelines extend or costs rise.
Authorized Share Increase Raises Dilution RiskDoubling authorized shares and enlarging the equity award pool structurally increases the company's capacity to issue stock for financing or compensation. While providing financial flexibility, this change elevates long‑term dilution risk for existing shareholders and can compress per‑share economics unless offset by clear value creation from approvals or commercial success.
Savara News
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $2.38 and its highest was $7.00 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $1.13B.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Aug 06, 2026 which is in 15 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on May 12, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.135 by -$0.015.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.14.
How many shares outstanding does Savara have?
Savara has 204,927,220 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.135. Following the earnings report the stock price went up 3.74%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Savara Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.17 (93.19% Upside)
$11.17 (93.19% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
142.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.08%
Trailing 12-Months
Company Description
Savara
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
SVRA Stock 12 Month Forecast
Average Price Target
$11.17
▲(93.19% Upside)
Technical Analysis
Ownership Overview
3.07% Insiders
7.48% Mutual Funds
0.14% Other Institutional Investors
77.73% Public Companies and
Individual Investors